21 November 2022 – Destiny Pharma’s AMR Paper

It is AMR Awareness Week!  The World Health Organisation has declared that Anti-Microbial Resistance (AMR) is one of the top 10 global public health threats facing humanity.  Destiny Pharma is developing novel anti-infectives, with a focus on infection prevention, to address the global challenge of AMR.  Read our AMR paper here.

18 November 2022 – Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Global threat of superbugs and AMR

AMR is associated with the deaths of five million people worldwide each year.  It has been estimated that, by 2050, the global death toll from AMR will rise to 10 million per year.

Destiny Pharma’s Chief Scientific Officer, Dr Bill Love, speaks to Proactive Investors about how Destiny is addressing the global threat of superbugs and AMR.  Click here for the full interview.

15 November 2022 – XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID

Brighton, United Kingdom, 15th November 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation.

This study is the second of two planned preclinical safety studies of the XF-73 Dermal formulation and will utilise a suite of preclinical services for interventional agent assessment (Contract No. HHSN272201800001I/75N93023F00001) held by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). The first study met its objectives and generated positive data as announced in February 2022. Following a US Food and Drug Administration (FDA) review of the first study, Destiny Pharma has completed further work developing both the dermal formulation and potential regulatory and clinical plans, which has cleared the path for progression into this second and final preclinical safety study.

Destiny Pharma is developing the novel formulation of XF-73 Dermal for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs) – up to 25% of US diabetic patients may suffer from DFUs in their lifetime and c. 13% have active ulcers. The XF-73 Dermal product is planned to be a fast, cost-effective dermal treatment that kills all relevant bacteria quickly, helping the wound heal and combatting the threat of Antimicrobial Resistance (AMR) through its novel, patented action.

Destiny Pharma will continue to work with NIAID to complete this preclinical safety package which will support future clinical development of XF-73 Dermal in serious wound infections. The study is planned to complete in Q2 2023 and should then be ready to move into clinical trials.

Neil Clark, CEO of Destiny Pharma, said: “We are very pleased with the continuing progress of our novel XF-73 Dermal infection programme which is targeted at meeting a clear clinical need driven by the increasing incidence of diabetes across the world. There are 29 million people diagnosed in the United States alone who are at risk of developing diabetic foot ulcer infections and peak product sales could reach half a billion US dollars. The start of this second preclinical study means that this programme is well placed to deliver a second clinical candidate in 2023 from our XF platform following the excellent Phase 2 clinical results generated for the XF-73 Nasal gel for the prevention of post-surgical infections caused by Staphylococcal aureus.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440

Optimum Strategic Communications
Nick Bastin, Manel Mateus, Eleanor Cooper
DestinyPharma@optimumcomms.com
+44 20 3922 0891

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

MC Associates AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-0

Stern IR – US
Janhavi Mohite
+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV™, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information, please visit  www.destinypharma.com

About XF-73

XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF‑73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

Dermal Infections

XF-73 is being developed as a new treatment for serious dermal infections such as diabetic foot ulcer infections (DFUs) to target a market which is estimated to be a $0.5 billion global sales opportunity based on the incidence of such infections, the costs of the associated medical care and a realistic product pricing of XF-73 in this new market. Driven by the growing number of diabetics and associated complications such as infected DFUs, this represents a significant market opportunity for XF-73. It is estimated that twenty-nine million people in US have a diagnosis of diabetes and of these 13% have active DFUs.

As with all anti-infectives, AMR is also a concern within this market. There is no dominant treatment for DFUs, and specialist physicians are therefore working to find better treatment options, including topical formulations. In addition, the target product profile of XF-73 tested favourably with dermal clinicians looking for better treatments for the smaller market for burns/wound infections and venous leg ulcers.

Destiny’s China partner CMS is also running a programme for XF-73 in superficial skin infections.

Forward-looking statements

Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.

07 September 2022 – Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference

Brighton, United Kingdom – 7 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that Destiny Pharma’s CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually.

The presentation will be available to view on demand from 1200 BST / 0700 ET on Monday 12 September 2022.  To join the conference virtually, view the presentation and ask any questions, please click on the link above to register.

Presentation Title:      Destiny Pharma Company Presentation

Presenter:                     Neil Clark

If you would like to meet with Destiny Pharma, please email us at conferences@destinypharma.com or contact us through the HC Wainwright conference meeting system if you are registered.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark / Manel Mateus /Vici Rabbetts
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com

MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12

Stern IR – US
Lilian Stern / Janhavi Mohite
+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

07 September 2022 – Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

  •  EMA endorses Destiny Pharma’s proposed single pivotal Phase 3 study design for the development of NTCD-M3 for the prevention of recurrence of Clostridioides difficile infections (CDI)
  • EMA endorses plans for the new patient-friendly NTCD-M3 capsule formulation

Brighton, United Kingdom – 7th September 2022 – Destiny Pharma plc (AIM: DEST), a late-stage clinical biotechnology company focused on the development of novel products to prevent life-threatening infectious diseases, is pleased to announce that it has received positive feedback from the European Medicine Agency (EMA) on the proposed NTCD-M3 Phase 3 development programme.

NTCD-M3 is the lead clinical candidate being developed by Destiny Pharma for the prevention of the recurrence of infections caused by toxic strains of the gut bacteria Clostridioides difficile, which can cause significant inflammation and damage to the gut leading to an estimated 29,000 deaths annually in the US alone, a number comparable to the yearly deaths from prostate cancer. It is estimated CDI adds an extra $6 billion to US healthcare costs per annum while in Europe, the economic burden caused by CDI is estimated at $3 billion and increasing.

The key points from the EMA’s feedback are that they have agreed:

  • With the overall comparability plans relating to the development of the new easy-to-use capsule formulation of NTCD-M3, thus lifting any requirements for human trials to demonstrate such comparability
  • That the proposed single trial Phase 3 design to be sufficient for a MAA (Marketing Authorisation Application) also endorsing the primary and secondary endpoints of the proposed Phase 3 study
  • That the overall proposed safety database will be collected through the conduct of the proposed Phase 3 trial and that this would be sufficient for a MAA
  • To remove the requirement of a thorough QT study (a study which is used to measure the potential impact of a drug on the heart function) for NTCD-M3 development programme

With EMA’s feedback received, Destiny Pharma is now focused on finalising the manufacturing and formulation of NTCD-M3 clinical trial material and on the detail of the global Phase 3 study with the aim of enrolling the first patient in the USA and potentially in Europe/rest of the world, towards the end of 2023. The Company is currently seeking partners to co-fund the Phase 3 clinical programme and take responsibility for the approval and commercialisation of NTCD-M3.

Dr. Yuri Martina, Chief Medical Officer of Destiny Pharma, said:

“NTCD-M3 is a unique microbiome product being a single strain of non-toxigenic Clostridioides difficile. This targeted mode of action differentiates it from FMT (faecal microbiota transplantation) or other multiple strains or consortia microbiome products and NTCD-M3 also has advantages from a safety and longer-term risk perspective. Importantly, the NTCD-M3 strain only transiently colonises the patient’s intestine which means it protects from CDI while allowing the normal microbiome to be rebuilt after antibiotic treatment. Additionally, NTCD-M3 delivers an impressive efficacy with recurrence rates reduced to around 5% when used immediately after the antibiotic treatment for CDI has been completed. As a physician, being able to prevent patients with CDI to go down the path of multiple recurrence is truly a game changer for the treatment of this disease.”

Dr. Mark Wilcox, Head of Research and Development in Microbiology at the Leeds Teaching Hospitals, commented:

“Early model and clinical trial data show that NTCD-M3 can effectively block the action of pathogenic C. difficile strains and so reduce the risk of recurrent CDI.  The results of the forthcoming Phase 3 trial are eagerly awaited to confirm the effectiveness of this non-antibiotic approach to reducing the risk of recurrent C. difficile infection.”

NTCD-M3 is a novel biotherapeutic for prevention of recurrence of CDI and it is composed of a single bacterial strain, a naturally occurring non-toxigenic C. difficile strain -M3. Rather than acting by restoring the microbiota after the antibiotics used to treat the infection have disrupted the gut microbiota it acts by colonising the gut with a harmless non-toxigenic strain of C. difficile, which prevents subsequent colonisation by toxigenic strains and allows the normal microbiota to recover on its own. NTCD-M3 colonisation is both safe and effective and does not permanently alter the microbiota.

If NTCD-M3 is successful in its planned Phase 3 trials in around 800 patients, it will be approved under a BLA (Biological Licence Application) by the FDA in the US for the prevention of recurrence in CDI and under a MAA in Europe.

The NTCD-M3 development focuses on patients with a primary episode of CDI and first recurrence. Thus, it is clearly differentiated from other products in development as NTCD-M3 is positioned as an early intervention to reduce the risk of recurrences.

According to the US Center for Disease Control and Prevention (CDC), C. difficile causes almost half a million infections in the USA each year. This number clearly indicates how significant the impact of C. difficile infections is on healthcare costs and the potential for NTCD-M3 to prevent these costs and to bring substantial value to healthcare systems and the patients in need. It represents a significant commercial opportunity for Destiny Pharma.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications 
Mary Clark / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12

Stern IR – USA
Lilian Stern / Janhavi Mohite
+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com

Forward looking statements

Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

22 August 2022 – Notice of Interim Results and Investor Presentation

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

Notice of Interim Results and Investor Presentation

Brighton, United Kingdom ‐ 22 August 2022 ‐ Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life‐threatening infections, will announce its interim results for the period ended 30th June 2022, on Thursday 8th September 2022.

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer, will provide a live presentation on the same day, at 10:00 am BST, followed by a Q&A session accessible via the Investor Meet Company platform. The webcast of the presentation will be available on the Company’s investor relations website at www.destinypharma.com.

The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until 09:00 am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:

https://www.investormeetcompany.com/destiny‐pharma‐plc/register‐investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

MC Services AG
Anne Hennecke / Andreas Burckhardt
+49‐211‐529252‐12

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life‐threatening infections. Its pipeline has novel microbiome‐based biotherapeutics and XF drug clinical assets including NTCD‐M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF‐73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post‐surgical staphylococcal hospital infections including MRSA. It is also co‐developing SPOR‐COVTM, a novel, biotherapeutic product for the prevention of COVID‐19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com

28 July 2022 – Chair’s Investor Update

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Chair’s Investor Update

Brighton, United Kingdom – 28 July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces an Investor Update from its Chair, Nick Rodgers.

“I am delighted with the progress we are making despite a difficult stock market, particularly in the life sciences sector, and the challenging economic background. At the fundraising in March, we undertook to complete two key tasks in 2022 – clarification of the XF-73 Nasal Phase 3 trial plan to prevent post-surgical Staphylococcus aureus infections with the US FDA and a partnering deal for our NTCD-M3 Clostridioides difficile Infections (CDI) prevention therapy. We have progressed both tasks and look forward to further successes during the remainder of this year.

XF-73 Nasal and NTCD-M3

Clarification has been received from the FDA on our XF-73 Nasal Phase 3 clinical trial plans. The details of this encouraging feedback were recently announced on 19th July. Additionally, we continue to progress partnering discussions on NTCD-M3 with the aim of announcing a deal before year end.

All the clinical data and competitor analyses we have reviewed and the market research we have undertaken gives us great confidence that both XF-73 and NTCD-M3, when approved by regulators, will deliver significant patient benefits and clear cost savings to hospitals and payers by reducing the incidence and expense of treating these life-threatening infections. Moreover, both have reported excellent Phase 2 clinical and safety data and show robust commercial models with the potential to generate over one US$ billion in peak sales.

I am particularly pleased that, within two years, we have been able to advance NTCD-M3 from its acquisition in November 2020 and develop the package through our expert regulatory, clinical and manufacturing efforts and are now close to delivering a partnering deal.  This is in line with the Company’s stated strategy of seeking partners to help co-fund the required Phase 3 development of our lead assets and lead the commercialization.

Other activity

While our focus remains on our two Phase 3 products we have sought to advance other aspects of our pipeline. Recently, we secured funding from the Cystic Fibrosis Foundation and also started a new research project targeted at Oral Mucositis. Our China partner, China Medical Systems, is carrying out pre-clinical work on their own XF-73 Dermal programme and SPOR-COV, our collaboration with SporeGen to develop a novel nasal spray to prevent viral respiratory infections, including COVID-19 and influenza, is in an exciting stage having almost completed the grant funded work.

I am extremely positive on the future of Destiny Pharma and I believe that our products can have a major impact in reducing infections worldwide and reduce healthcare costs. Our commitment to infection prevention is more relevant than ever and we have a very large opportunity to create significant value for our stakeholders including patients, healthcare systems and payers.”

Nick Rodgers

Chair

For further information please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications 
Mary Clark / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

 MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com

Forward looking statements

Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.